株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

酸性スフィンゴミエリナーゼ欠損症(ASMD):市場洞察、疫学、市場予測 2028年

Acid sphingomyelinase deficiency (ASMD) - Market Insights, Epidemiology and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 911508
出版日 ページ情報 英文 125 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.55円で換算しております。
Back to Top
酸性スフィンゴミエリナーゼ欠損症(ASMD):市場洞察、疫学、市場予測 2028年 Acid sphingomyelinase deficiency (ASMD) - Market Insights, Epidemiology and Market Forecast - 2028
出版日: 2019年09月01日 ページ情報: 英文 125 Pages
概要

新興10カ国(トルコ、ロシア、サウジアラビア、アラブ首長国連邦、メキシコ、コロンビア、ブラジル、アルゼンチン、中国、台湾)の2017年の酸性スフィンゴミエリナーゼ欠損症(ASMD)の有病者数は8,799人、その市場規模は120万米ドルと推計されています。

当レポートでは、新興10カ国(トルコ、ロシア、サウジアラビア、アラブ首長国連邦、メキシコ、コロンビア、ブラジル、アルゼンチン、中国、台湾)の酸性スフィンゴミエリナーゼ欠損症(ASMD)市場を調査し、市場および疾患の概要、表現型・臨床症状・国別の疫学的予測、アンメットニーズ、新薬の概要、全体および各国の市場規模の推移と予測、市場の成長要因および障壁の分析などをまとめています。

目次

第1章 重要洞察

第2章 酸性スフィンゴミエリナーゼ欠損症(ASMD)の概要

  • 分布状況(実績値)
  • 分布状況(予測値)

第3章 疾患背景と概要

  • イントロダクション
  • 歴史
  • 病型別
    • NPD-A(ニーマン・ピック病 A型)
    • NPD-B(ニーマン・ピック病 B型)
  • 病因
  • 症状
  • 病態生理
  • 診断
  • バイオマーカー

第4章 疫学と患者人口

  • 主な調査結果
  • キーオピニオンリーダーの意見

第5章 新興10カ国の酸性スフィンゴミエリナーゼ欠損症(ASMD)の総罹患数

  • 総有病数
  • 診断有病数

第6章 酸性スフィンゴミエリナーゼ欠損症(ASMD)の国別疫学

  • 仮定と理論的根拠
  • 中国
    • 総有病数
    • 診断件数
    • 診断件数:表現型別
    • 診断件数:臨床症状別
  • 台湾
    • 総有病数
    • 診断件数
    • 診断件数:臨床表現型別
    • 診断件数:臨床症状別
  • サウジアラビア
    • 総有病数
    • 診断件数
    • 診断件数:臨床表現型別
    • 診断件数:臨床症状別
  • アラブ首長国連邦
    • 総有病数
    • 診断件数
    • 診断件数:臨床表現型別
    • 診断件数:臨床症状別
  • ロシア
    • 総有病数
    • 診断件数
    • 診断件数:臨床表現型別
    • 診断件数:臨床症状別
  • トルコ
    • 総有病数
    • 診断件数
    • 診断件数:臨床表現型別
    • 診断件数:臨床症状別
  • メキシコ
    • 総有病数
    • 診断件数
    • 診断件数:臨床表現型別
    • 診断件数:臨床症状別
  • ブラジル
    • 総有病数
    • 診断件数
    • 診断件数:臨床表現型別
    • 診断件数:臨床症状別
  • アルゼンチン
    • 総有病数
    • 診断件数
    • 診断件数:臨床表現型別
    • 診断件数:臨床症状別
  • コロンビア
    • 総有病数
    • 診断件数
    • 診断件数:臨床表現型別
    • 診断件数:臨床症状別

第7章 酸性スフィンゴミエリナーゼ欠損症(ASMD)の治療と管理

第8章 アンメットニーズ

第9章 新薬

  • Olipudase Alfa:Sanofi
    • 製品説明
    • その他の開発活動
    • 臨床開発
    • 安全性と有効性
    • 長所と短所
    • 製品プロファイル

第10章 酸性スフィンゴミエリナーゼ欠損症(ASMD):新興国の分析

  • 主な調査結果
  • キーオピニオンリーダーの意見
  • 新興国(10カ国)の市場規模
    • 市場規模:治療薬別

第11章 市場見通し:国別

  • 新興市場:市場の見通し
  • 中国
    • 総市場規模
    • 市場規模:治療薬別
  • 台湾
  • サウジアラビア
  • アラブ首長国連邦
  • ロシア
  • トルコ
  • メキシコ
  • ブラジル
  • アルゼンチン
  • コロンビア

第12章 市場の成長要因

第13章 市場の障壁

第14章 付録

  • 報告方法

第15章 DelveInsightのサービス内容

第16章 免責事項

図表

List of Tables

  • Table 1: Characteristics of ASMD Subtypes
  • Table 2: Sign and Symptoms of ASMD
  • Table 3: Total Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets (2017-2028)
  • Table 4: Diagnosed Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets (2017-2028)
  • Table 5: Total Prevalent Cases of ASMD in China (2017-2028)
  • Table 6: Diagnosed Cases of ASMD in China (2017-2028)
  • Table 7: Total Prevalent Cases of ASMD by clinical phenotype in China (2017-2028)
  • Table 8: Total Prevalent Cases of ASMD based on clinical manifestations in China (2017-2028)
  • Table 9: Total Prevalent Cases of ASMD in Taiwan (2017-2028)
  • Table 10: Diagnosed Cases of ASMD in Taiwan (2017-2028)
  • Table 11: Total Prevalent Cases of ASMD by clinical phenotype in Taiwan (2017-2028)
  • Table 12: Total Prevalent Cases of ASMD based on clinical manifestations in Taiwan (2017-2028)
  • Table 13: Total Prevalent Cases of ASMD in Saudi Arabia (2017-2028)
  • Table 14: Diagnosed Cases of ASMD in Saudi Arabia (2017-2028)
  • Table 15: Total Prevalent Cases of ASMD by clinical phenotype in Saudi Arabia (2017-2028)
  • Table 16: Total Prevalent Cases of ASMD based on clinical manifestations in Saudi Arabia (2017-2028)
  • Table 17: Total Prevalent Cases of ASMD in UAE (2017-2028)
  • Table 18: Diagnosed Cases of ASMD in UAE (2017-2028)
  • Table 19: Total Prevalent Cases of ASMD by clinical phenotype in UAE (2017-2028)
  • Table 20: Total Prevalent Cases of ASMD based on clinical manifestations in UAE (2017-2028)
  • Table 21: Total Prevalent Cases of ASMD in Russia (2017-2028)
  • Table 22: Diagnosed Cases of ASMD in Russia (2017-2028)
  • Table 23: Total Prevalent Cases of ASMD by clinical phenotype in Russia (2017-2028)
  • Table 24: Total Prevalent Cases of ASMD based on clinical manifestations in Russia (2017-2028)
  • Table 25: Total Prevalent Cases of ASMD in Turkey (2017-2028)
  • Table 26: Diagnosed Cases of ASMD in Turkey (2017-2028)
  • Table 27: Total Prevalent Cases of ASMD by clinical phenotype in Turkey (2017-2028)
  • Table 28: Total Prevalent Cases of ASMD based on clinical manifestations in Turkey (2017-2028)
  • Table 29: Total Prevalent Cases of ASMD in Mexico (2017-2028)
  • Table 30: Diagnosed Cases of ASMD in Mexico (2017-2028)
  • Table 31: Total Prevalent Cases of ASMD by clinical phenotype in Mexico (2017-2028)
  • Table 32: Total Prevalent Cases of ASMD based on clinical manifestations in Mexico (2017-2028)
  • Table 33: Total Prevalent Cases of ASMD in Brazil (2017-2028)
  • Table 34: Diagnosed Cases of ASMD in Brazil (2017-2028)
  • Table 35: Total Prevalent Cases of ASMD by clinical phenotype in Brazil (2017-2028)
  • Table 36: Total Prevalent Cases of ASMD based on clinical manifestations in Brazil (2017-2028)
  • Table 37: Total Prevalent Cases of ASMD in Argentina (2017-2028)
  • Table 38: Diagnosed Cases of ASMD in Argentina (2017-2028)
  • Table 39: Total Prevalent Cases of ASMD by clinical phenotype in Argentina (2017-2028)
  • Table 40: Total Prevalent Cases of ASMD based on clinical manifestations in Argentina (2017-2028)
  • Table 41: Total Prevalent Cases of ASMD in Colombia (2017-2028)
  • Table 42: Diagnosed Cases of ASMD in Colombia (2017-2028)
  • Table 43: Total Prevalent Cases of ASMD by clinical phenotype in Colombia (2017-2028)
  • Table 44: Total Prevalent Cases of ASMD based on clinical manifestations in Colombia (2017-2028)
  • Table 45: Olipudase alfa, Clinical Trial Description, 2019
  • Table 46: Total Market Size of ASMD in 10 Emerging Markets in USD Million (2017-2028)
  • Table 47: Total Market Size of ASMD by Therapies in 10 Emerging Markets in USD Million (2017-2028)
  • Table 48: Total Market Size of ASMD in China, USD Million (2017-2028)
  • Table 49: China Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Table 50: Market Size of ASMD in Taiwan, USD Million (2017-2028)
  • Table 51: Taiwan Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Table 52: Market Size of ASMD in the Saudi Arabia, USD Million (2017-2028)
  • Table 53: Saudi Arabia Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Table 54: Market Size of ASMD in U.A.E., USD Million (2017-2028)
  • Table 55: U.A.E. Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Table 56: Market Size of ASMD in Russia, USD Million (2017-2028)
  • Table 57: Russia Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Table 58: Market Size of ASMD in Turkey, USD Million (2017-2028)
  • Table 59: Turkey Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Table 60: Market Size of ASMD in Mexico, USD Million (2017-2028)
  • Table 61: Mexico Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Table 62: Market Size of ASMD in Brazil, USD Million (2017-2028)
  • Table 63: Brazil Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Table 64: Market Size of ASMD in Argentina, USD Million (2017-2028)
  • Table 65: Argentina Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Table 66: Market Size of ASMD in Colombia, USD Million (2017-2028)
  • Table 67: Colombia Market Size of ASMD by Therapies in USD Million (2017-2028)

List of Figures

  • Figure 1: The SMPD1 gene on Chromosome 11
  • Figure 2: The autosomal recessive inheritance of ASMD
  • Figure 3: Symptoms of Acid Sphingomyelinase Deficiency.
  • Figure 4: Clinical Manifestations of NPD-B By Organ Class
  • Figure 5: The Metabolic pathway of Niemann-Pick type-A and type-B
  • Figure 6: The Diagnostic Algorithm of ASMD
  • Figure 7: Total Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets (2017-2028)
  • Figure 8: Diagnosed Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets (2017-2028)
  • Figure 9: Total Prevalent Cases of ASMD in China (2017-2028)
  • Figure 10: Diagnosed Cases of ASMD in China (2017-2028)
  • Figure 11: Total Prevalent Cases of ASMD by clinical phenotype in China (2017-2028)
  • Figure 12: Total Prevalent Cases of ASMD based on clinical manifestations in China (2017-2028)
  • Figure 13: Total Prevalent Cases of ASMD in Taiwan (2017-2028)
  • Figure 14: Diagnosed Cases of ASMD in Taiwan (2017-2028)
  • Figure 15: Total Prevalent Cases of ASMD by clinical phenotype in Taiwan (2017-2028)
  • Figure 16: Total Prevalent Cases of ASMD based on clinical manifestations in Taiwan (2017-2028)
  • Figure 17: Total Prevalent Cases of ASMD in Saudi Arabia (2017-2028)
  • Figure 18: Diagnosed Cases of ASMD in Saudi Arabia (2017-2028)
  • Figure 19: Total Prevalent Cases of ASMD by clinical phenotype in Saudi Arabia (2017-2028)
  • Figure 20: Total Prevalent Cases of ASMD based on clinical manifestations in Saudi Arabia (2017-2028)
  • Figure 21: Total Prevalent Cases of ASMD in UAE (2017-2028)
  • Figure 22: Diagnosed Cases of ASMD in UAE (2017-2028)
  • Figure 23: Total Prevalent Cases of ASMD by clinical phenotype in UAE (2017-2028)
  • Figure 24: Total Prevalent Cases of ASMD based on clinical manifestations in UAE (2017-2028)
  • Figure 25: Total Prevalent Cases of ASMD in Russia (2017-2028)
  • Figure 26: Diagnosed Cases of ASMD in Russia (2017-2028)
  • Figure 27: Total Prevalent Cases of ASMD by clinical phenotype in Russia (2017-2028)
  • Figure 28: Total Prevalent Cases of ASMD based on clinical manifestations in Russia (2017-2028)
  • Figure 29: Total Prevalent Cases of ASMD in Turkey (2017-2028)
  • Figure 30: Diagnosed Cases of ASMD in Turkey (2017-2028)
  • Figure 31: Total Prevalent Cases of ASMD by clinical phenotype in Turkey (2017-2028)
  • Figure 32: Total Prevalent Cases of ASMD based on clinical manifestations in Turkey (2017-2028)
  • Figure 33: Total Prevalent Cases of ASMD in Mexico (2017-2028)
  • Figure 34: Diagnosed Cases of ASMD in Mexico (2017-2028)
  • Figure 35: Total Prevalent Cases of ASMD by clinical phenotype in Mexico (2017-2028)
  • Figure 36: Total Prevalent Cases of ASMD based on clinical manifestations in Mexico (2017-2028)
  • Figure 37: Total Prevalent Cases of ASMD in Brazil (2017-2028)
  • Figure 38: Diagnosed Cases of ASMD in Brazil (2017-2028)
  • Figure 39: Total Prevalent Cases of ASMD by clinical phenotype in Brazil (2017-2028)
  • Figure 40: Total Prevalent Cases of ASMD based on clinical manifestations in Brazil (2017-2028)
  • Figure 41: Total Prevalent Cases of ASMD in Argentina (2017-2028)
  • Figure 42: Diagnosed Cases of ASMD in Argentina (2017-2028)
  • Figure 43: Total Prevalent Cases of ASMD by clinical phenotype in Argentina (2017-2028)
  • Figure 44: Total Prevalent Cases of ASMD based on clinical manifestations in Argentina (2017-2028)
  • Figure 45: Total Prevalent Cases of ASMD in Colombia (2017-2028)
  • Figure 46: Diagnosed Cases of ASMD in Colombia (2017-2028)
  • Figure 47: Total Prevalent Cases of ASMD by clinical phenotype in Colombia (2017-2028)
  • Figure 48: Total Prevalent Cases of ASMD based on clinical manifestations in Colombia (2017-2028)
  • Figure 49: Treatment modalities for ASMD
  • Figure 50: Unmet Needs
  • Figure 51: Total Market Size of ASMD in 10 Emerging Markets in USD Million (2017-2028)
  • Figure 52: Total Market Size of ASMD by Therapies in 10 Emerging Markets in USD Million (2017-2028)
  • Figure 53: Total Market Size of ASMD in China, USD Million (2017-2028)
  • Figure 54: China Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Figure 55: Market Size of ASMD in Taiwan, USD Million (2017-2028)
  • Figure 56: Taiwan Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Figure 57: Market Size of ASMD in the Saudi Arabia, USD Million (2017-2028)
  • Figure 58: Saudi Arabia Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Figure 59: Market Size of ASMD in U.A.E., USD Million (2017-2028)
  • Figure 60: U.A.E. Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Figure 61: Market Size of ASMD in Russia, USD Million (2017-2028)
  • Figure 62: Russia Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Figure 63: Market Size of ASMD in Turkey, USD Million (2017-2028)
  • Figure 64: Turkey Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Figure 65: Market Size of ASMD in Mexico, USD Million (2017-2028)
  • Figure 66: Mexico Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Figure 67: Market Size of ASMD in Brazil, USD Million (2017-2028)
  • Figure 68: Brazil Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Figure 69: Market Size of ASMD in Argentina, USD Million (2017-2028)
  • Figure 70: Argentina Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Figure 71: Market Size of ASMD in Colombia, USD Million (2017-2028)
  • Figure 72: Colombia Market Size of ASMD by Therapies in USD Million (2017-2028)
  • Figure 73: Market Drivers
  • Figure 74:Market Barriers
目次
Product Code: DIMI0674

DelveInsight's 'Acid sphingomyelinase deficiency (ASMD) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of ASMDs in the 10 Emerging Markets (EM) ,i.e., Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acid sphingomyelinase deficiency (ASMD) from 2017 to 2028 segmented by ten emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • Asia (China and Taiwan)
  • Middle East (Turkey, Saudi Arabia, UAE)
  • Eastern Europe (Russia)
  • LATAM (Brazil, Mexico, Colombia and Argentina)

Study Period: 2017-2028

Acid sphingomyelinase deficiency (ASMD) - Disease Understanding and Treatment Algorithm

Acid sphingomyelinase deficiency (ASMD) is a rare progressive genetic disorder that results from a deficiency of the enzyme acid sphingomyelinase, which is required to break down (metabolize) a fatty substance (lipid) called sphingomyelin and inherited in an autosomal recessive pattern. Acid sphingomyelinase, E.C. 3.1.4.12, (ASM) is a lysosomal phosphodiesterase enzyme that hydrolyzes sphingomyelin, a phospholipid storage substance found in the brain, liver, lungs, spleen and lymph nodes, to ceramide and phosphorylcholine. It is also known as Niemann-Pick disease.

The DelveInsight Acid sphingomyelinase deficiency (ASMD) market report gives the thorough understanding of the Acid sphingomyelinase deficiency by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acid sphingomyelinase deficiency in Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.

Acid sphingomyelinase deficiency Epidemiology

The Acid sphingomyelinase deficiency (ASMD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 emerging countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Acid sphingomyelinase deficiency, diagnosed cases of ASMD by clinical phenotype, and diagnosed cases of ASMD based on clinical manifestations) scenario of Acid sphingomyelinase deficiency (ASMD) in the 10EM covering Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan) from 2017-2028.

According to DelveInsight, the total number of prevalent cases of Acid sphingomyelinase deficiency (ASMD) in 10 EM was found to be 8,799, in the year 2017.

Acid sphingomyelinase deficiency Drug Chapters

This segment of the Acid sphingomyelinase deficiency report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The treatment scenario in emerging markets is more or less same as in the United States and Europe. There is a tremendous lack of effective supportive therapies (especially for the infantile cases), let alone curative ones with the severe infantile neurovisceral phenotype encountering death by 3 years of age. Although the other less severe forms have a normal lifespan but a certain section die prematurely due to respiratory insufficiency and liver disease. Statins form the mainstay of treatment regimen used to treat hyperlipidemia characterized by low high-density lipoprotein (HDL) cholesterol in NPD Type B adult cases.

Acid sphingomyelinase deficiency Market Outlook

The Acid sphingomyelinase deficiency market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Acid sphingomyelinase deficiency in 10EM was found to be USD 1.2 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 10EM, China accounts for the largest market size of Acid sphingomyelinase deficiency, in comparison to Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, and Taiwan.

Acid sphingomyelinase deficiency Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acid sphingomyelinase deficiency Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Acid sphingomyelinase deficiency Report Key Strengths

  • 10 Year Forecast
  • 10EM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Acid sphingomyelinase deficiency Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Acid sphingomyelinase deficiency market
  • Organize sales and marketing efforts by identifying the best opportunities for Acid sphingomyelinase deficiency market
  • To understand the future market competition in the Acid sphingomyelinase deficiency market.

Table of Contents

1. Key Insights

2. Acid sphingomyelinase deficiency Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Acid sphingomyelinase deficiency in 2017
  • 2.2. Market Share (%) Distribution of Acid sphingomyelinase deficiency in 2028

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. History
  • 3.3. Sub-types
    • 3.3.1. NPD-A
    • 3.3.2. NPD-B
  • 3.4. Etiology of ASMD
  • 3.5. Sign and Symptoms
  • 3.6. Pathophysiology of ASMD
  • 3.7. Diagnosis
    • 3.7.1. Based on Chronic Visceral and Non-visceral ASMD
    • 3.7.2. Based on Other Diseases
  • 3.8. Biomarkers

4. Epidemiology and Patient Population - By Region

  • 4.1. Key Findings
  • 4.2. KOL Views

5. Ten Emerging Markets (EM) Total Prevalent Patient Population of Acid sphingomyelinase deficiency (ASMD)

  • 5.1. Total Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets
  • 5.2. Diagnosed Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets

6. Country Wise-Epidemiology of Acid sphingomyelinase deficiency (ASMD)

  • 6.1. Emerging Markets: Assumptions and Rationale
  • 6.2. China
    • 6.2.1. Total Prevalent Cases of ASMD in China
    • 6.2.2. Diagnosed Cases of ASMD in China
    • 6.2.3. Diagnosed Cases of ASMD by clinical phenotype in China
    • 6.2.4. Diagnosed Cases of ASMD based on clinical manifestations in China
  • 6.3. Taiwan
    • 6.3.1. Total Prevalent Cases of ASMD in Taiwan
    • 6.3.2. Diagnosed Cases of ASMD in Taiwan
    • 6.3.3. Diagnosed Cases of ASMD by clinical phenotype in Taiwan
    • 6.3.4. Diagnosed Cases of ASMD based on clinical manifestations in Taiwan
  • 6.4. Saudi Arabia
    • 6.4.1. Total Prevalent Cases of ASMD in Saudi Arabia
    • 6.4.2. Diagnosed Cases of ASMD in Saudi Arabia
    • 6.4.3. Diagnosed Cases of ASMD by clinical phenotype in Saudi Arabia
    • 6.4.4. Diagnosed Cases of ASMD based on clinical manifestations in Saudi Arabia
  • 6.5. U.A.E.
    • 6.5.1. Total Prevalent Cases of ASMD in UAE
    • 6.5.2. Diagnosed Cases of ASMD in UAE
    • 6.5.3. Diagnosed Cases of ASMD by clinical phenotype in UAE
    • 6.5.4. Diagnosed Cases of ASMD based on clinical manifestations in UAE
  • 6.6. Russia
    • 6.6.1. Total Prevalent Cases of ASMD in Russia
    • 6.6.2. Diagnosed Cases of ASMD in Russia
    • 6.6.3. Diagnosed Cases of ASMD by clinical phenotype in Russia
    • 6.6.4. Diagnosed Cases of ASMD based on clinical manifestations in Russia
  • 6.7. Turkey
    • 6.7.1. Total Prevalent Cases of ASMD in Turkey
    • 6.7.2. Diagnosed Cases of ASMD in Turkey
    • 6.7.3. Diagnosed Cases of ASMD by clinical phenotype in Turkey
    • 6.7.4. Diagnosed Cases of ASMD based on clinical manifestations in Turkey
  • 6.8. Mexico
    • 6.8.1. Total Prevalent Cases of ASMD in Mexico
    • 6.8.2. Diagnosed Cases of ASMD in Mexico
    • 6.8.3. Diagnosed Cases of ASMD by clinical phenotype in Mexico
    • 6.8.4. Diagnosed Cases of ASMD based on clinical manifestations in Mexico
  • 6.9. Brazil
    • 6.9.1. Total Prevalent Cases of ASMD in Brazil
    • 6.9.2. Diagnosed Cases of ASMD in Brazil
    • 6.9.3. Diagnosed Cases of ASMD by clinical phenotype in Brazil
    • 6.9.4. Diagnosed Cases of ASMD based on clinical manifestations in Brazil
  • 6.10. Argentina
    • 6.10.1. Total Prevalent Cases of ASMD in Argentina
    • 6.10.2. Diagnosed Cases of ASMD in Argentina
    • 6.10.3. Diagnosed Cases of ASMD by clinical phenotype in Argentina
    • 6.10.4. Diagnosed Cases of ASMD based on clinical manifestations in Argentina
  • 6.11. Colombia
  • 6.12. Total Prevalent Cases of ASMD in Colombia
  • 6.13. Diagnosed Cases of ASMD in Colombia
  • 6.14. Diagnosed Cases of ASMD by clinical phenotype in Colombia
  • 6.15. Diagnosed Cases of ASMD based on clinical manifestations in Colombia

7. Treatment and Management of Acid sphingomyelinase deficiency

8. Unmet Needs

9. Emerging Therapies

  • 9.1. Olipudase Alfa: Sanofi
    • 9.1.1. Product Description
    • 9.1.2. Other development Activities
    • 9.1.3. Clinical Development
    • 9.1.4. Safety and Efficacy
    • 9.1.5. Advantages and Disadvantages
    • 9.1.6. Product Profile

10. Acid sphingomyelinase deficiency: 10 EM Analysis

  • 10.1. Key Findings
  • 10.2. KOL Views
  • 10.3. Market Size of ASMD in 10 EM
    • 10.3.1. Market Size of ASMD by Therapies

11. Market Outlook by Country

  • 11.1. Emerging Markets: Market Outlook
  • 11.2. China
    • 11.2.1. Total Market Size of ASMD
    • 11.2.2. Market Size of ASMD by Therapies
  • 11.3. Taiwan
    • 11.3.1. Total Market Size of ASMD
    • 11.3.2. Market Size of ASMD by Therapies
  • 11.4. Saudi Arabia
    • 11.4.1. Total Market Size of ASMD
    • 11.4.2. Market Size of ASMD by Therapies
  • 11.5. U.A.E.
    • 11.5.1. Total Market Size of ASMD
    • 11.5.2. Market Size of ASMD by Therapies
  • 11.6. Russia
    • 11.6.1. Total Market Size of ASMD
    • 11.6.2. Market Size of ASMD by Therapies
  • 11.7. Turkey
    • 11.7.1. Total Market Size of ASMD
    • 11.7.2. Market Size of ASMD by Therapies
  • 11.8. Mexico
    • 11.8.1. Total Market Size of ASMD
    • 11.8.2. Market Size of ASMD by Therapies
  • 11.9. Brazil
    • 11.9.1. Total Market Size of ASMD
    • 11.9.2. Market Size of ASMD by Therapies
  • 11.10. Argentina
    • 11.10.1. Total Market Size of ASMD
    • 11.10.2. Market Size of ASMD by Therapies
  • 11.11. Colombia
    • 11.11.1. Total Market Size of ASMD
    • 11.11.2. Market Size of ASMD by Therapies

12. Market Drivers

13. Market Barriers

14. Appendix

  • 14.1. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

Back to Top